Skip to main content

SQ, TDOC, VRTX: Cathie Wood is optimistic about doubling stocks


When Cathie Wood buys stocks, investors will follow her to buy, which seems to be the latest trend in the investment world.

 In the popular saying, following Cathie Wood, there is money to be made.  Even some time ago due to the rise in U.S. Treasury yields, technology stocks plummeted, and ARK funds suffered a frantic sell-off. Wood is still as stable as a mountain, and he issued a statement saying that everything was as early as we expected and was better than we expected.  Technology stocks are a good time to buy bottoms and increase positions.  Today, I will analyze Cathie Wood's heavy holdings from the company's fundamentals and future market prospects. Can it double in the long run?

 Square (ranked first in ARKK's innovative technology ETF)

 The financial technology giant Square is a revolutionary stock in the financial industry, breaking the traditional payment industry.  Square is known for its seller ecosystem, which provides small businesses with point-of-sale solutions and analytical tools.  In return, Square collects merchant fees as revenue from the gross payment volume (Gross Payment Volume, GPV) of the network.  Between 2012 and 2019, this GPV soared from US$6.5 billion to US$106.2 billion.  Although GPV may decline in 2020 due to the epidemic, the compound annual growth rate from 2012 to 2019 is 49%, indicating that it will return to its previous level in 2021.

 It is worth noting that the Square seller ecosystem has been very effective in attracting larger merchants in recent years.  Merchants with an average annual GPV of at least US$125,000 in the third quarter of 2020 accounted for 61% of the total GPV.  Because this is a merchant fee-driven business, so more large companies use the platform to make Square make more money.  Cash App had more than 36 million active users in the fourth quarter, an increase of 50% over the same period last year.  Square is also gradually increasing the features available on the Cash App, making it more and more popular for individuals to conduct a wide range of financial transactions.

 Of course, Square's peer-to-peer payment platform Cash App provides the largest amount of business.  As millennials promote more digital payment methods, the monthly active user base of Cash App has surged (7 million at the end of 2017 and 30 million by mid-2020).  Cash App provides Square with a variety of income collection methods, including payment transfer fees, merchant fees, investment, and bitcoin exchange fees.  Cash App should become the main driver of the company's gross profit in 2021.

 Overall, Square is a value growth stock.  The company's current market value is about 103 billion US dollars, which is equivalent to 196 times PE and 7.8 times PS.

 Square achieved initial success by providing payment processing services for small and medium businesses.  Over time, the company expanded its products and services to include point-of-sale software, e-commerce platforms, payroll services, business debit cards, etc.  Starting this month, Square now also operates a federally chartered bank.  This opened the door for Square to provide small business loans to its customers.

 The current transition from cash to digital payment is still in its infancy.  Square is expected to grow through its sellers and Cash App ecosystem, and in the process will bring substantial benefits to investors.

 Teladoc Health (Leader in Telemedicine)

 Due to the epidemic, the development of telemedicine has made real progress in 2020.  Teladoc Health is one of the biggest winners.  Its stock price soared by nearly 140%.

 However, so far, TDOC is still in the early stages of telemedicine.  According to data, after the epidemic is over, the annual telemedicine market in the United States will grow to about 250 billion US dollars. If the international market is added, this number will be even greater, and TDOC will be less than 30 billion US dollars.  There is still enough space.

 TDOC should be the biggest beneficiary among them.  Although Amazon announced plans to launch Amazon Care telemedicine services to its American employees this summer.  Amazon also intends to provide the service to other companies later in 2021 to participate in the competition in the telemedicine market.  But Mu Ji disagrees, thinking that Amazon will not pose a threat to TDOC.  Continue to increase TDOC.

 Sister Mu believes that TDOC is the global leader in virtual care.  So far, more than 40% of Fortune 500 companies use TDOC's services, and it provides more comprehensive products than its competitors.  The most important thing is that the growth prospects of TDOC are very broad, and the development space of telemedicine is large enough.  Coupled with TDOC's acquisition of Livongo Health, which operates a digital health platform that can help individuals manage chronic diseases, which creates a huge cross-selling opportunity.

 Vertex Pharmaceuticals

 ARK Genomic Revolution ETF ranked sixth

 Vertex Pharmaceuticals (VRTX) is currently the strongest performer among all the top stocks of Wood's ETF.  Large biotech companies do not have any competitors in their core markets.  Vertex's four approved cystic fibrosis drugs are the only drugs that treat the underlying cause of genetic diseases.

 Vertex also uses its expertise to target other rare genetic diseases.  It expects to report the key results of a Phase 2 study evaluating VX-864 in the treatment of liver disease alpha-1 antitrypsin deficiency in the next few months.  The company's product line also includes candidates for rare blood diseases β thalassemia and sickle cell disease and rare kidney disease focal segmental glomerulosclerosis.

 And Vertex has the potential to change conventional treatment methods, and this treatment has just entered Phase 1/2 research.  If the cell therapy VX-880 succeeds in clinical trials, it may be able to enable type 1 diabetes patients to live independently of insulin.

 Vertex has a cash reserve of 6.6 billion U.S. dollars and plans to use it to recruit mid- and late-stage candidates to further strengthen its product line.  In the next few years, this biotech stock will continue to be a big winner.  In the long run, both financial technology and telemedicine are closely related to people’s lives. These are the general trends in which people’s living habits are being reshaped and the new trends in future technological development. These general trends may be in the next few decades.  In the span, change the global social, economic, and political landscape.  It is believed that investors will continue to benefit from these changes and generate high returns.

Comments

Popular posts from this blog

Bitcoin vs Ethereum vs Dogecoin: Which one is suitable to buy?

 Bitcoin(BTC), Ethereum(ETH), and Dogecoin(DOGE) are the three most-watched cryptocurrencies.  As a young investor, he has a strong mentality of pursuing returns and accepting new things. In recent years, cryptocurrencies have become the new favorites of many people. In particular, these three digital currencies have attracted the most attention: Bitcoin, Ethereum, and Dogecoin.  However, not all cryptocurrencies are created equally and trying to determine which type is right for you can cause confusion.  Each currency has advantages and disadvantages, and which currency you choose to invest in will depend on your situation.  Investing in cryptocurrency must bear the risk  First of all, you must consider whether cryptocurrencies are suitable for you because all cryptocurrencies are highly speculative and subject to great volatility. They have experienced the "currency disaster" in recent weeks, with an adjustable-rate of more than 30%.    Fur...

My long-term stock market trading strategy!

trading strategy As a stock market investor, everyone has an investment trading strategy. Through my many years of investment experience, I have tried different investment strategies, used different investment tools, and concluded my own set of investment strategies.  This is a long-term investment strategy, not a short-term one. For ordinary investors, how to cope with the big ups and downs of the stock market, and by sharing my investment trading strategy, I hope that it can help investors and enable the asset portfolio to add value steadily. First, when the stock market is at different stages, I will use different coping methods. There are usually three stages in the stock market, and I generally use three different approaches. First, the stock market is in a rising phase. I usually do not use leveraged instruments or make financial loans to trade. Although leveraged trading can make quick and large profits, it can also make quick and large losses.  When trading wi...

AMD stock forecast 2025: Q2 is expected to perform strongly

Before the US stock market on July 19, US technology stocks continued their decline last Friday, and AMD's stock price also continued to fall.  AMD will announce the results of the second quarter of 2021 on July 27. The market expects this performance to be strong, so this round of decline may be a great opportunity to buy the stock.  financial indicator  Due to the strong market demand for CPU and graphics cards in 2021, AMD’s revenue is expected to exceed the maximum value of the financial guidance. AMD’s C&G business is expected to grow the most because higher-priced AMD Ryzen and high-end AMD Radeon sales continue to increase.  In terms of gross profit margin, the market expects AMD's gross profit margin in Q2 2021 will increase by 47% year-on-year.  If the average selling prices of CPUs and GPUs continue to rise in Q2 of 2021, and the ASPs of CPUs and GPUs will increase in Q1 of 2021, the gross profit margin may also increase by 48%.  CPU market sh...

TSM Stock Forecast and Price Target 2021

Today, I will analyze TSMC stocks in-depth with you. In the semiconductor sector, TSMC has always been my most promising stock. TSMC has just announced its results for the fourth quarter of 2020. At the same time, there are new developments in the entire chip industry recently. Therefore, today I will combine the financial report and chips. The latest developments in the industry to analyze the trend of TSMC stocks, First of all, we analyze TSMC’s fourth-quarter and full-year 2020 financial reports to see what are the key points worthy of investors’ attention. First, TSMC’s fourth-quarter revenue and profitability are very good.  Compared with the outlook for Q4 in Q3, the outlook at that time was US$12.4-12.7 billion, and the actual revenue was US$12.68 billion. Actual revenue As the upper limit of the outlook, the gross profit margin outlook is 51.5%-53.5%, while the actual gross profit margin is 54%, which is better than the outlook. The operating net profit margin is expected t...

Cloudflare's 4Q 2021 earnings report

 Just took a look at Cloudflare's (NET) 4Q 2021 earnings report. Cloudflare is in an area that covers several hot spots, including content delivery networks, i.e. CDNs, cloud computing, and cybersecurity. For the Cloudflare quarterly report, here is a summary: 1) Revenue of $194 million (then expected 4Q revenue in the range of $184 to $185 million), up 52% year-over-year ($172 million in 2021, up 51% year-over-year). 2) The number of customers continues to grow rapidly, with the total number of customers has reached 1416 (1260 in the previous quarter). 3) Non-GAAP gross margin was 79.2% vs. 78.1% in the same quarter last year (vs. 79.2% in 3Q vs. 77.3% in the same quarter last year.) Non-GAAP net income has started to turn around, meaning it has started to be profitable. 4) Revenue is expected to be in the range of $205 to $206 million in 4Q. That works out to about 6% YoY growth. Cloudflare had good results this time, beating its previous guidance. Revenues are still growing at a...

Investors have begun to switch back to traditional growth stocks

 On Thursday, the stock prices of Cisco, Alphabet, and IBM hit new highs. But more importantly, the previously unpopular speculative growth stocks, including stocks bought by many ARK funds, have now begun to rebound.  How is this going?  Investors' perspective on the market is changing. In the first quarter of this year, mainstream voices in the market believe that the economy will restart strongly, bond yields will rise, and inflation may become a problem later this year. After the end of the first quarter, these expectations were only partially fulfilled.  The U.S. economy has indeed restarted strongly, but bond yields fell in the first quarter instead of rising because investors began to believe:  1) Inflation and supply chain disruption may indeed be "temporary", as the Fed insists;  2) The second and third quarters will be the highest points of stock returns and economic growth.  Alec Young, a chief investment officer of Tactical Alpha, said: “...

TSMC VS Nvidia, AMD, Intel. How to choose semiconductor stocks?

The general pattern of the semiconductor industry, the overall trend and target price of TSMC in 2021, how the Nvidia(NVDA), AMD, and Intel(INTC) semiconductor stocks are laid out, what is the decisive factors, and whether there is a predictable time point, we conducted a more systematic discussion.  The big picture of the semiconductor industry The semiconductor industry is cyclical. Since the second half of 2019, global semiconductors have entered a new round of the business cycle. This is very important. Only when you understand this reason can you hold stocks with peace of mind. The following analysis is based on the time dimension. In the short term, looking at one to three months now, with the outbreak of the epidemic again, the production capacity of 8-inch wafers are in short supply, the semiconductor industry chain is out of stock, wafer foundry, packaging, and testing links have seen price increases, and production capacity is in short supply. High economic situation, In ...

NIO and Tesla(TSLA) stock forecast 2025: released important news

  In the past two days, two electric vehicle companies, NIO and Tesla have released important news.  However, the market gave mixed reactions, one rose and the other fell. Let's take a look at what happened.  To  NIO stock forecast 2025  Let me talk about NIO first.  NIO announced this morning that the company will issue additional shares totaling US$2 billion. The price of the additional issuance will be based on the current market price, and the timing of the issuance will be determined according to the company’s needs. It may be a one-time sale or a share.  Wholesale sale.  After calculation, this will cause about a 3% equity dilution for existing shareholders.  However, the market seems to have given more interpretation. Today, NIO's share price has fallen by 6.3%, which is more than twice the theoretical dilution.  To  From the prospectus, the company only stated broadly that the funds raised will be used to strengthen its bala...

PLTR stock forecast 2025: Cathie Woods increased Palantir stock position

Software company Palantir (PLTR) released the latest quarterly earnings report, which performed very well.  After the financial report, Palantir's stock price soared to 14.64% at the highest point. At the same time, the keen Cathie Woods also bought $140 million in Palantir stock.  I won't talk about Palantir's specific business. If you don't know much about it, you can go back to my previous article.  Let's talk back to the financial report.  Benefiting from the benefits of the US government’s contract renewal, Palantir’s earnings per share and total revenue both beat expectations for this quarter’s earnings report.  Among them, earnings per share were $0.04, beating the expected $0.01; total revenue was 376 million, an increase of 49% from the same period last year, slightly higher than the expected $361 million.  Although the extent of beating expectations is not very large, the biggest highlight of the financial report is to broaden the business.  ...

VRTX stock forecast 2025: Vertex is undervalued

Let's look at some biotech companies with stable cash flow and currently undervalued value stocks as targets for diversified portfolios.  The company I shared today, called Vertex Pharmaceuticals (VRTX), is dedicated to the development of rare diseases, especially Cystic Fibrosis (CF). I have always had high respect for the rare disease group of pharmaceutical companies in the disease category. In addition, in the future, gene and cell therapies are subverting the role of rare diseases in the pharmaceutical industry, making rare diseases no longer uncommon. It's tasteless, but a field full of the future. Vertex Pharmaceuticals Inc. was established in 1989 by Joshua Boger and Kevin Kinsella. is headquartered in Boston. At that time, several very good research and development companies were established in the United States, including the aforementioned Regeneron, Gilead, and today's Vertex.  Vertex In the past, he devoted himself to the development of small molecule drugs, wh...